The Relationship between Resveratrol and Diabetes Mellitus

Document Type : Review Article

Authors

1 PhD Candidate, Food Security Research Center, School of Nutrition and Food Science, Isfahan University of Medical Science, Isfahan, Iran

2 Associate Professor, Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Science, Isfahan, Iran

Abstract

Background: Resveratrol belongs to a large group of biologically active substances found in plants which are classified as phytoestrogen because of their ability to interact with estrogen receptors. Several beneficial effects of resveratrol are described in the literature such as cardioprotective, anti-cancer, anti-inflammatory and antioxidant actiosn. There are Conflicting evidence about the beneficial effects of resveratrol in treatment and prevention of diabetic complications. So, we decided to explore them in this review.Methods: Related articles from Google scholar, PubMed, Scopus databases from 2000 to 2010 were searched.Conclusion: Several useful effects of resveratrol in prevention and treatment of diabetes mellitus were recorded. However, almost all of the studies were conducted in animals that regarding the possible effects in human, similar studies should be proposed in them.

Keywords

References

  1. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29)Suppl 1): S43-S48.
  2. Zahedi HS, Jazayeri S, Ghiasvand R, Djalali M, Eshraghian MR. Effects of polygonum cuspidatum containing resveratrol on inflammation in male professional basketball players. Int J Prev Med 2013; 4(Suppl 1): S1-S4.
  3. Roggero JP, Garciaparrilla C. Effects of ultraviolet irradiation on resveratrol and changes in resveratrol and various of its derivatives in the skins of ripening grapes. Sci Aliments 1995; 15(5): 411-22.
  4. Burns J, Yokota T, Ashihara H, Lean ME, Crozier A. Plant foods and herbal sources of resveratrol. J Agric Food Chem 2002; 50(11): 3337-40.
  5. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J 2003; 17(14): 1975-85.
  6. Sbaghi M, Jeandet P, Faivre B, Bessis R, Fournioux JC. Development of methods using phytoalexin (resveratrol) assessment as a selection criterion to screen grapevine in vitro cultures for resistance to grey mould (Botrytis cinerea). Euphytica 1995; 86(1): 41-7.
  7. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275(5297): 218-20.
  8. Bertelli AA, Das DK. Grapes, wines, resveratrol, and heart health. J Cardiovasc Pharmacol 2009; 54(6): 468-76.
  9. Askari Gh, Ghiasvand R, Hajishafiee M, Akbari F. The effects of quercetin supplementation on endothelial function, oxidative stress, athletic performance, inflammatory biomarkers and muscle damage indices in athletes. J Isfahan Med Sch 2012; 29(165): 2246-52. [In Persian].
  10. Frojdo S, Durand C, Pirola L. Metabolic effects of resveratrol in mammals--a link between improved insulin action and aging. Curr Aging Sci 2008; 1(3): 145-51.
  11. Szkudelska K, Szkudelski T. Resveratrol, obesity and diabetes. Eur J Pharmacol 2010; 635(1-3): 1-8.
  12. Bloomgarden ZT. Diabetes complications. Diabetes Care 2004; 27(6): 1506-14.
  13. Palumbo PJ. Gycemic control, mealtime glucose excursions, and diabetic complications in type 2 diabetes mellitus. Mayo Clin Proc 2001; 76(6): 609-18.
  14. Cheng AY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005; 172(2): 213-26.
  15. Lekli I, Szabo G, Juhasz B, Das S, Das M, Varga E, et al. Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am J Physiol Heart Circ Physiol 2008; 294(2): H859-H866.
  16. Sharma S, Misra CS, Arumugam S, Roy S, Shah V, Davis JA, et al. Antidiabetic activity of resveratrol, a known SIRT1 activator in a genetic model for type-2 diabetes. Phytother Res 2011; 25(1): 67-73.
  17. Palsamy P, Subramanian S. Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats. Chem Biol Interact 2009; 179(2-3): 356-62.
  18. Silan C. The effects of chronic resveratrol treatment on vascular responsiveness of streptozotocin-induced diabetic rats. Biol Pharm Bull 2008; 31(5): 897-902.
  19. Szkudelski T. Resveratrol-induced inhibition of insulin secretion from rat pancreatic islets: evidence for pivotal role of metabolic disturbances. Am J Physiol Endocrinol Metab 2007; 293(4): E901-E907.
  20. Palsamy P, Subramanian S. Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic beta-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats. J Cell Physiol 2010; 224(2): 423-32.
  21. Su HC, Hung LM, Chen JK. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 2006; 290(6): E1339-E1346.
  22. Juan ME, Vinardell MP, Planas JM. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 2002; 132(2): 257-60.
  23. Schmatz R, Schetinger MR, Spanevello RM, Mazzanti CM, Stefanello N, Maldonado PA, et al. Effects of resveratrol on nucleotide degrading enzymes in streptozotocin-induced diabetic rats. Life Sci 2009; 84(11-12): 345-50.
  24. Chi TC, Chen WP, Chi TL, Kuo TF, Lee SS, Cheng JT, et al. Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats. Life Sci 2007; 80(18): 1713-20.
  25. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127(6): 1109-22.
  26. Breen DM, Sanli T, Giacca A, Tsiani E. Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. Biochem Biophys Res Commun 2008; 374(1): 117-22.
  27. Deng JY, Hsieh PS, Huang JP, Lu LS, Hung LM. Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and -independent pathways. Diabetes 2008; 57(7): 1814-23.
  28. Penumathsa SV, Thirunavukkarasu M, Zhan L, Maulik G, Menon VP, Bagchi D, et al. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J Cell Mol Med 2008; 12(6A): 2350-61.
  29. Schmatz R, Mazzanti CM, Spanevello R, Stefanello N, Gutierres J, Maldonado PA, et al. Ectonucleotidase and acetylcholinesterase activities in synaptosomes from the cerebral cortex of streptozotocin-induced diabetic rats and treated with resveratrol. Brain Res Bull 2009; 80(6): 371-6.
  30. Thirunavukkarasu M, Penumathsa SV, Koneru S, Juhasz B, Zhan L, Otani H, et al. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 2007; 43(5): 720-9.
  31. Park HJ, Yang JY, Ambati S, Della-Fera MA, Hausman DB, Rayalam S, et al. Combined effects of genistein, quercetin, and resveratrol in human and 3T3-L1 adipocytes. J Med Food 2008; 11(4): 773-83.
  32. Szkudelski T. The insulin-suppressive effect of resveratrol - an in vitro and in vivo phenomenon. Life Sci 2008; 82(7-8): 430-5.
  33. Szkudelski T. Resveratrol inhibits insulin secretion from rat pancreatic islets. Eur J Pharmacol 2006; 552(1-3): 176-81.
  34. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444(7117): 337-42.
  35. Barger JL, Kayo T, Vann JM, Arias EB, Wang J, Hacker TA, et al. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 2008; 3(6): e2264.
  36. Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 2000; 49(11): 1751-60.
  37. Lee JH, Song MY, Song EK, Kim EK, Moon WS, Han MK, et al. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes 2009; 58(2): 344-51.
  38. Lenzen S. Oxidative stress: the vulnerable beta-cell. Biochem Soc Trans 2008; 36(Pt 3): 343-7.
  39. Robertson RP. Oxidative stress and impaired insulin secretion in type 2 diabetes. Curr Opin Pharmacol 2006; 6(6): 615-9.
  40. Sun C, Zhang F, Ge X, Yan T, Chen X, Shi X, et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 2007; 6(4): 307-19.
  41. Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010; 59(3): 554-63.
  42. Rivera L, Moron R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 2009; 77(6): 1053-63.
  43. Shang J, Chen LL, Xiao FX. Resveratrol improves high-fat induced nonalcoholic fatty liver in rats. Zhonghua Gan Zang Bing Za Zhi 2008; 16(8): 616-9. [In Chinese].
  44. Shang J, Chen LL, Xiao FX, Sun H, Ding HC, Xiao H. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 2008; 29(6): 698-706.
  45. Rocha KK, Souza GA, Ebaid GX, Seiva FR, Cataneo AC, Novelli EL. Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets. Food Chem Toxicol 2009; 47(6): 1362-7.
  46. Szkudelska K, Nogowski L, Szkudelski T. Resveratrol and genistein as adenosine triphosphate-depleting agents in fat cells. Metabolism 2011; 60(5): 720-9.
  47. Szkudelska K, Nogowski L, Szkudelski T. Resveratrol, a naturally occurring diphenolic compound, affects lipogenesis, lipolysis and the antilipolytic action of insulin in isolated rat adipocytes. J Steroid Biochem Mol Biol 2009; 113(1-2): 17-24.
  48. Kennedy A, Overman A, Lapoint K, Hopkins R, West T, Chuang CC, et al. Conjugated linoleic acid-mediated inflammation and insulin resistance in human adipocytes are attenuated by resveratrol. J Lipid Res 2009; 50(2): 225-32.
  49. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 2010; 285(11): 8340-51.
  50. Pinent M, Castell A, Baiges I, Montagut G, Arola L, Ardevol A. Bioactivity of flavonoids on insulin-secreting cells. Comprehensive Reviews in Food Science and Food Safety 2008; 7(4): 299-308.
  51. Zahedi M, Ghiasvand R, Feizi A, Asgari G, Darvish L. Does Quercetin Improve Cardiovascular Risk factors and Inflammatory Biomarkers in Women with Type 2 Diabetes: A Double-blind Randomized Controlled Clinical Trial. Int J Prev Med 2013; 4(7): 777-85.
  52. Hambrock A, de Oliveira Franz CB, Hiller S, Grenz A, Ackermann S, Schulze DU, et al. Resveratrol binds to the sulfonylurea receptor (SUR) and induces apoptosis in a SUR subtype-specific manner. J Biol Chem 2007; 282(5): 3347-56.
  53. Zhang Y, Jayaprakasam B, Seeram NP, Olson LK, DeWitt D, Nair MG. Insulin secretion and cyclooxygenase enzyme inhibition by cabernet sauvignon grape skin compounds. J Agric Food Chem 2004; 52(2): 228-33.
  54. Chen WP, Chi TC, Chuang LM, Su MJ. Resveratrol enhances insulin secretion by blocking K(ATP) and K(V) channels of beta cells. Eur J Pharmacol 2007; 568(1-3): 269-77.
  55. Slater SJ, Seiz JL, Cook AC, Stagliano BA, Buzas CJ. Inhibition of protein kinase C by resveratrol. Biochim Biophys Acta 2003; 1637(1): 59-69.
  56. Atten MJ, Godoy-Romero E, Attar BM, Milson T, Zopel M, Holian O. Resveratrol regulates cellular PKC alpha and delta to inhibit growth and induce apoptosis in gastric cancer cells. Invest New Drugs 2005; 23(2): 111-9.
  57. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000; 141(10): 3657-67.
  58. Zhang J. Resveratrol inhibits insulin responses in a SirT1-independent pathway. Biochem J 2006; 397(3): 519-27.
  59. Frojdo S, Cozzone D, Vidal H, Pirola L. Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem J 2007; 406(3): 511-8.
  60. Ramadori G, Gautron L, Fujikawa T, Vianna CR, Elmquist JK, Coppari R. Central administration of resveratrol improves diet-induced diabetes. Endocrinology 2009; 150(12): 5326-33.
Journal of Isfahan Medical School
Volume 32, Issue 310 - Serial Number 310
September and October 2015
Pages 1993-2005

Files

History

  • Receive Date: 07 January 2014
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics